Ballabio C B, Caruso I
MMW Munch Med Wochenschr. 1978 Sep 22;120(38):1219-22.
Experience in therapy with sulindac and S-adenosyl-L-methionine (SAMe) is reported. Sulindac is an indene derivative which is particularly indicated in degenerative skeletal diseases and is essentially free from the well-known side-effects of traditional analgesics. The results of therapy were good in 75%. SAMe is the most important methyl group donor and is consequently responsible for the methylation (inactivation) of histamine, upon which its antiphlogistic action is based. SAMe is also particularly involved in the transfer of sulfate groups in the body. Sulfur compounds are esentially involved in the synthesis of cartilage. The short-term trials with SAMe were altogether more favorable than the longterm trials, yet there was a longterm effect in about half the cases.
报告了舒林酸和S-腺苷-L-蛋氨酸（SAMe）的治疗经验。舒林酸是一种茚衍生物，特别适用于退行性骨骼疾病，并且基本没有传统镇痛药的众所周知的副作用。75%的治疗效果良好。SAMe是最重要的甲基供体，因此负责组胺的甲基化（失活），其抗炎作用基于此。SAMe还特别参与体内硫酸基团的转移。硫化合物主要参与软骨的合成。SAMe的短期试验总体上比长期试验更有利，但约一半的病例有长期效果。
